Litigation Details for Novo Nordisk Inc. v. Mylan Institutional LLC (D. Del. 2019)
✉ Email this page to a colleague
Novo Nordisk Inc. v. Mylan Institutional LLC (D. Del. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-08-20 |
| Court | District Court, D. Delaware | Date Terminated | 2021-04-06 |
| Cause | 35:271 Patent Infringement | Assigned To | Kent A. Jordan |
| Jury Demand | None | Referred To | Sherry R. Fallon |
| Parties | MYLAN INSTITUTIONAL LLC | ||
| Patents | 6,268,343; 7,762,994; 8,114,833; 8,579,869; 8,846,618; 9,155,776; 9,265,893; RE41,956 | ||
| Attorneys | Jason James Rawnsley | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novo Nordisk Inc. v. Mylan Institutional LLC
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in Novo Nordisk Inc. v. Mylan Institutional LLC
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Novo Nordisk Inc. v. Mylan Institutional LLC (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-10-15 | Proposed] Order of Dismissal Regarding the RE41,956 Patent. Signed by Judge Colm F. Connolly on 10/15/…2019 6 April 2021 1:19-cv-01551 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | ||
| 2019-08-20 | 1 | Complaint | United States Patent Nos. 6,268,343 (the “’343 patent”), 7,762,994 (the “’994 patent”), 8,114,833 (the… COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 6,268,343 21. Novo Nordisk re-alleges…(the “’833 patent”), 8,579,869 (the “’869 patent”), 8,846,618 (the “’618 patent”), 9,265,893 (the “’893… 1. This is an action for patent infringement under the patent laws of the United States, Title…’893 patent”), and RE41,956 (the “RE ’956 patent”), which cover inter alia, Victoza® and/or its use. | External link to document |
| 2020-10-08 | 110 | Notice of Service | Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 6,268,343; 8,114,833; 8,846,618; 9,265,893; and RE41,956…2019 6 April 2021 1:19-cv-01551 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-10-08 | 111 | Notice of Service | Initial Invalidity Contentions Regarding U.S. Patent Nos. 6,268,343; 8,114,833; 8,846,618; 9,265,893; and RE41,956…2019 6 April 2021 1:19-cv-01551 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-10-13 | 112 | Stipulation of Dismissal | Proposed] Order of Dismissal Regarding the RE41,956 Patent -- by Novo Nordisk A/S, Novo Nordisk Inc.. …2019 6 April 2021 1:19-cv-01551 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-11-05 | 115 | Notice of Service | Claim 39 of U.S. Patent No. 6,268,343; (2) Robert Boyd Regarding Invalidity of U.S. Patent No. 9,265,893;…Paul Dalby Regarding Invalidity of U.S. Patent Nos. 6,268,343, 8,114,833 and 8,846,618; and (4) Dr. Peter…Peter Flatt Regarding Invalidity of U.S. Patent No. 6,268,343 filed by Mylan Institutional LLC.(Ewing,…2019 6 April 2021 1:19-cv-01551 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
